By: Staff Reporter From: genomeweb.com The US Food and Drug Administration on Wednesday approved capmatinib (Novartis’ Tabrecta) for treatment of patients with metastatic non-small cell lung cancer. The agency also approved Foundation Medicine’s FoundationOne CDx assay, a broad comprehensive genomic profiling test for solid tumors, as a companion diagnostic for the drug. A companion diagnostic for capmatinib with Foundation’s liquid …
-
-
Deepest Gratitude From This Breast Cancer Survivor on Veterans Day to All Who Have Served
-
From a Breast Cancer Survivor, the Holidays Are the Perfect Time to Discuss the Family Medical History
-
Why This Breast Cancer Survivor Loves the Holiday Season
-
Wardrobe Concerns After Breast Cancer
-
What About the Other 11 Months After October for Breast Cancer Awareness
